

Task Force on Climate-related Financial Disclosures Report

— Continued

Metrics & Targets

Pfizer calculates Scope 1 and 2 emissions in accordance with the GHG Protocol (revised edition). Our 2020 GHG footprint (including Scope 3 categories 1-8 and 15) was independently assured pursuant to ISAE 3000 (revised) by ERM CVS and verification of 2021 data is underway. Emissions are reported annually in our CDP response and are broken down by type, country and business division. We also track metrics relative to our business continuity and disaster recovery programs (e.g., number of supplier assessments completed; sites with fully implemented plans for the management of risk associated with natural perils such as flooding and severe weather, noting it is not possible to state with certainty whether individual weather events are a result of climate change).

Pfizer discloses our Scope 1, Scope 2 and Scope 3 emissions annually through our [CDP submittal](#) and publishes our Scope 1+2 emissions in our ESG Report (formerly in our Annual Review) and on our [website](#).

We have achieved three consecutive GHG reduction goals (2000-2007, 2007-2012, and 2012-2020) and have reduced our GHG emissions over 60% since 2000. We remain committed to ambitious long-term actions and have announced our ambition to become carbon neutral across our internal operations, procuring 100% renewable electricity and delivering a 46% absolute reduction in Scope 1 and 2 emissions from a 2019 baseline. Any remaining emissions will be offset through carbon credits. Additionally, recognizing that Scope 3 emissions account for 80% of our carbon footprint, we also commit to reducing emissions related to upstream logistics by 10% and business travel by 25% by 2025 from a 2019 baseline, and to use our influence to catalyze similar reductions across our value chain.